Status:
WITHDRAWN
About Oral and Gut Microbiota in Intensive Care Unit : SARS-CoV-2 (COVID-19) Infection Impact.
Lead Sponsor:
University Hospital, Toulouse
Conditions:
SARS-CoV-2 Acute Respiratory Disease
Eligibility:
All Genders
18+ years
Brief Summary
The objective of the present study is to describe the negative impact on oral and gut microbiota of a severe acute respiratory syndrome SARS-CoV-2 infection in patients hospitalized in intensive care ...
Detailed Description
Gut microbiota in ICU patients is sorely distorted, there is an important loss of diversity which can be traduced by a decrease of commensal bacteria and an increase of pathogens. The virulence, infec...
Eligibility Criteria
Inclusion
- Controls:
- \- Hospitalized patient with non-SARS-CoV-2 hypoxemic pneumonia
- Patients COVID 19:
- \- Patient hospitalized for SARS-CoV-2 hypoxemic pneumonia
- All:
- Patient hospitalized for less than 48 hours in a general intensive care unit
- Patient who has given free, informed and express (oral) consent to participate in the research (or a close relative or trusted person of the patient if the patient cannot express himself/herself)
- Patient covered by a social security system or equivalent
- Expected hospitalization of more than 48 hours
Exclusion
- gut inflammatory disease
- recent gut surger
- ostomy
- recent antibiotics
- artificial nutrition in the long term
Key Trial Info
Start Date :
June 15 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 15 2025
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04913142
Start Date
June 15 2021
End Date
February 15 2025
Last Update
October 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital of Toulouse
Toulouse, France